文献速递新药、器械与细胞基因治疗研发真实世界研究与卫生经济

欧洲药品管理局两种加速审批路径中验证与未验证替代终点的使用情况:2011-2018年获批产品的横断面研究

The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
PubMed 文献 · PLoS Med · 2019-09-10

该横断面研究通过欧洲公共评估报告识别2011年1月1日至2018年12月31日经条件上市许可(CMA)或加速评估(AA)获批产品的关键试验主要终点,共纳入51个产品(26个CMA,25个AA)。46个产品(90%)基于替代终点获批,未发现验证这些替代终点的研究;大多数替代终点按已发表分级被评为「合理可能」或「生物学合理性」预测临床结局。作者结论认为加速审批的关键试验证据主要基于未验证的替代终点。

要点

  • 51个经CMA或AA获批产品中,46个(90%)基于替代终点获批,仅5个(10%)基于临床结局获批。
  • 未发现验证这些替代终点预测临床结局的研究。
  • 49个报告替代终点的产品中,30个(61%)被评为「合理可能」,46个(94%)被评为具有「生物学合理性」。

核心结论

  • 支持CMA或AA获批产品的关键试验证据主要基于未验证的替代终点。
  • 欧洲公共评估报告及产品特征摘要(包括患者信息 leaflets)需一致说明支持加速审批的关键试验终点的性质与局限性,以使处方者和患者了解实际临床获益证据的不足。
  • 对于基于未验证替代终点获批的产品,监管机构需对上市许可持有人施加批准后措施以确认临床获益。

研究设计与样本

  • 横断面研究,使用欧洲公共评估报告识别2011年1月1日至2018年12月31日经CMA或AA获批产品关键试验的主要终点。
  • 排除疫苗、局部用药、逆转剂或出血预防剂以及在研究时间范围内撤回的产品。
  • 共51个产品符合纳入标准,其中26个经CMA,25个经AA。
  • 26个产品为肿瘤适应症,10个为感染,8个为遗传性疾病,7个为其他系统疾病。
  • 对报告替代终点的关键试验,在PubMed检索预测临床结局的验证证据,并使用2种已发表分级评估验证水平。

主要发现

  • 5个产品(10%),均为AA,基于报告临床结局的关键试验获批;46个产品(90%)基于替代终点获批。
  • 未发现验证这些替代终点的研究。
  • 在49个报告替代终点的产品中,大多数按已发表分级被评为「合理可能」(n=30;61%)或具有「生物学合理性」(n=46;94%)预测临床结局。
  • 欧洲公共评估报告未一致解释支持获批的关键试验终点的性质、替代终点是否经过验证,或描述确认性上市后研究将报告的终点。

关键数值与推荐

  • 有随机对照试验支持替代终点-临床结局关系的替代终点评为「已验证」。
  • 49个报告替代终点的产品中,30个(61%)被评为「合理可能」,46个(94%)被评为具有「生物学合理性」。

局限性

  • 可能遗漏了相关的验证研究。
  • findings适用于2种加速审批路径,可能无法推广至经标准评估路径获批的产品。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In situations of unmet medical need or in the interests of public health, expedited approval pathways, including conditional marketing authorisation (CMA) and accelerated assessment (AA), speed up European Medicines Agency (EMA) marketing authorisation recommendations for medicinal products. CMAs are based on incomplete benefit-risk assessment data and authorisation remains conditional until regulator-imposed confirmatory postmarketing measures are fulfilled. For products undergoing AA, complete safety and efficacy data should be available, and postauthorisation measures may include only standard requirements of risk management and pharmacovigilance plans. In the pivotal trials supporting products assessed by expedited pathways, surrogate endpoints reduce drug development time compared with waiting for the intended clinical outcomes. Whether surrogate endpoints supporting products authorised through CMA and AA pathways reliably predict clinical benefits of therapy has not been studied systematically. Our objectives were to determine the extent to which surrogate endpoints are used and to assess whether their validity had been confirmed according to published hierarchies. METHODS AND FINDINGS: We used European Public Assessment Reports (EPARs) to identify the primary endpoints in the pivotal trials supporting products authorised through CMA or AA pathways during January 1, 2011 to December 31, 2018. We excluded products that were vaccines, topical, reversal, or bleeding prophylactic agents or withdrawn within the study time frame. Where pivotal trials reported surrogate endpoints, we conducted PubMed searches for evidence of validity for predicting clinical outcomes. We used 2 published hierarchies to assess validity level. Surrogates with randomised controlled trials supporting the surrogate-clinical outcome relationship were rated as 'validated'. Fifty-one products met the inclusion criteria; 26 underwent CMAs, and 25 underwent AAs. Overall, 26 products were for oncology indications, 10 for infections, 8 for genetic disorders, and 7 for other systems disorders. Five products (10%), all AAs, were authorised based on pivotal trials reporting clinical outcomes, and 46 (90%) were authorised based on surrogate endpoints. No studies were identified that validated the surrogate endpoints. Among a total of 49 products with surrogate endpoints reported, most were rated according to the published hierarchies as being 'reasonably likely' (n = 30; 61%) or of having 'biological plausibility' (n = 46; 94%) to predict clinical outcomes. EPARs did not consistently explain the nature of the pivotal trial endpoints supporting authorisations, whether surrogate endpoints were validated or not, or describe the endpoints to be reported in the confirmatory postmarketing studies. Our study has limitations: we may have overlooked relevant validation studies; the findings apply to 2 expedited pathways and may not be generalisable to products authorised through the standard assessment pathway. CONCLUSIONS: The pivotal trial evidence supporting marketing authorisations for products granted CMA or AA was based dominantly on nonvalidated surrogate endpoints. EPARs and summary product characteristic documents, including patient information leaflets, need to state consistently the nature and limitations of endpoints in pivotal trials supporting expedited authorisations so that prescribers and patients appreciate shortcomings in the evidence about actual clinical benefit. For products supported by nonvalidated surrogate endpoints, postauthorisation measures to confirm clinical benefit need to be imposed by the regulator on the marketing authorisation holders.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Schuster Bruce C, Brhlikova P, Heath J, et al. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. PLoS Med. 2019. PMID: 31504034. doi:10.1371/journal.pmed.1002873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。